Press Releases

Press Releases

Nov 12, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/12/11 -- Enzon Pharmaceuticals, Inc.
Nov 3, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 11/03/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the third quarter of 2011.
Oct 17, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 10/17/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced that Ana I.
Sep 22, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is implementing a plan to reduce its workforce and operating costs to more closely align its resources with the Company's research and development activities.
Aug 4, 2011
PISCATAWAY, NJ -- (MARKET WIRE) -- 08/04/11 -- Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) today announced its financial results for the second quarter of 2011.
May 31, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Ana I. Stancic has been named Senior Vice President and Chief Financial Officer of the Company, effective June 8, 2011 . Ms.
May 19, 2011
PEG-SN38 Clinical Programs Continue in Metastatic Breast Cancer, Other Solid Tumors PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.
May 6, 2011
--Investments in R&D translating to continued progress with oncology pipeline-- PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the first quarter of 2011.
Apr 5, 2011
Third-Generation mRNA Antagonists Continue Showing Promise in Expanding Range of Oncology Indications Locked Nucleic Acid Technology to be Featured in RNA-Targeting Therapeutics Symposium PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc.
Mar 17, 2011
PISCATAWAY, N.J. --(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that Richard C. Mulligan , Ph.D., has been appointed Vice-Chairman of the Board of Directors, effective immediately. Dr.